• Collaboration with leading global pharmaceutical company AstraZeneca in Brazil
• First contract supporting Australia's National Lung Cancer Screening Program with Spectrum Medical Imaging
• Contracts expected to drive significant growth over time

4DMedical Limited, a global leader in respiratory imaging technology, has provided supplementary information about its recent ASX announcement. The key details include a collaboration with the leading global pharmaceutical company AstraZeneca in Brazil, as well as a contract with Spectrum Medical Imaging to support Australia's National Lung Cancer Screening Program. While the Spectrum Medical Imaging contract is not expected to be immediately material in terms of revenues, it is an important milestone as 4DMedical's first contract supporting this national screening program and is expected to grow significantly over time. The announcement highlights 4DMedical's continued progress in expanding its global footprint and partnerships to drive the adoption of its advanced respiratory imaging solutions.